A Single Masked, Randomized Comparison of the Safety and Efficacy of 0.2 and 0.5 µg/Day Fluocinolone Acetonide/Medidur in Patients With Exudative Age Related Macular Degeneration Who Have Received Lucentis

Trial Profile

A Single Masked, Randomized Comparison of the Safety and Efficacy of 0.2 and 0.5 µg/Day Fluocinolone Acetonide/Medidur in Patients With Exudative Age Related Macular Degeneration Who Have Received Lucentis

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2014

At a glance

  • Drugs Fluocinolone acetonide (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms MAP
  • Most Recent Events

    • 16 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top